Eximis Surgical is developing the Eximis Laparoscopic Specimen Removal System to provide fast, fully contained segmentation and removal of large specimens through small laparoscopic incisions. The platform is designed to keep incisions small throughout minimally invasive procedures and aims to fill a clinical gap in specimen removal. The company announced it secured $8.7 million in financing to support its development and regulatory progress. Proceeds will be used to fund U.S. regulatory activities for the system. The Eximis system is not yet available for sale in the U.S. Eximis is based in Louisville, Colo., and its board includes co-founder and CEO Donna Ford-Serbu alongside industry executives and investors. Eximis Surgical develops the Eximis Laparoscopic Specimen Removal System, which is designed to keep incisions small during minimally invasive procedures by providing contained specimen segmentation and removal. The system integrates multiple containment bags and a novel cutting technology that eliminates the need for sharps during segmentation. Led by co‑founder and CEO Kristin Johnson, the company is preparing for regulatory and commercial milestones. The device is not currently approved for commercial use. Eximis intends to use new capital to pursue U.S. regulatory approval and fund the commercial launch of the system. The company is headquartered in Louisville, Colorado.

Total raised

$16M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2024